Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 6
2005 12
2006 24
2007 65
2008 99
2009 118
2010 131
2011 151
2012 176
2013 216
2014 173
2015 187
2016 124
2017 105
2018 98
2019 48
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

1,518 results
Results by year
Filters applied: . Clear all
Page 1
Lapatinib.
Voigtlaender M, Schneider-Merck T, Trepel M. Voigtlaender M, et al. Recent Results Cancer Res. 2018;211:19-44. doi: 10.1007/978-3-319-91442-8_2. Recent Results Cancer Res. 2018. PMID: 30069757 Review.
A pharmacokinetic study on lapatinib in type 2 diabetic rats.
Karbownik A, Szałek E, Sobańska K, Klupczynska A, Plewa S, Grabowski T, Wolc A, Moch M, Kokot ZJ, Grześkowiak E. Karbownik A, et al. Pharmacol Rep. 2018 Apr;70(2):191-195. doi: 10.1016/j.pharep.2017.09.003. Epub 2017 Sep 18. Pharmacol Rep. 2018. PMID: 29471066
Optimal treatment of early stage HER2-positive breast cancer.
Pernas S, Barroso-Sousa R, Tolaney SM. Pernas S, et al. Cancer. 2018 Dec 1;124(23):4455-4466. doi: 10.1002/cncr.31657. Epub 2018 Oct 6. Cancer. 2018. PMID: 30291791 Free article. Review.
Treatment of advanced HER2-positive breast cancer: 2018 and beyond.
Pondé N, Brandão M, El-Hachem G, Werbrouck E, Piccart M. Pondé N, et al. Cancer Treat Rev. 2018 Jun;67:10-20. doi: 10.1016/j.ctrv.2018.04.016. Epub 2018 May 2. Cancer Treat Rev. 2018. PMID: 29751334 Review.
The concomitant use of lapatinib and paracetamol - the risk of interaction.
Karbownik A, Szałek E, Sobańska K, Grabowski T, Klupczynska A, Plewa S, Wolc A, Magiera M, Porażka J, Kokot ZJ, Grześkowiak E. Karbownik A, et al. Invest New Drugs. 2018 Oct;36(5):819-827. doi: 10.1007/s10637-018-0573-1. Epub 2018 Feb 20. Invest New Drugs. 2018. PMID: 29464465 Free PMC article.
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams LS, Gradishar WJ. Johnston SRD, et al. J Clin Oncol. 2018 Mar 10;36(8):741-748. doi: 10.1200/JCO.2017.74.7824. Epub 2017 Dec 15. J Clin Oncol. 2018. PMID: 29244528 Clinical Trial.
1,518 results
Jump to page
Feedback